Page last updated: 2024-09-05

lenalidomide and T-Cell Lymphoma

lenalidomide has been researched along with T-Cell Lymphoma in 11 studies

Research

Studies (11)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	8 (72.73)	24.3611
2020's	3 (27.27)	2.80

Authors

Authors	Studies
Adelman, K; Amaka, S; de Leval, L; Donaldson, NL; Donovan, KA; Duffy, J; Fischer, ES; Gaulard, P; Hagner, PR; Heavican-Foral, TB; Iqbal, J; Jain, S; Jones, MK; Koch, R; Liu, H; Nelson, GM; Ng, SY; Nirmal, AJ; Nowak, RP; Powers, F; Stevenson, KE; Thakurta, A; Trevisani, C; Weinstock, DM; Wu, G; Wu, W; Xu, R; Yang, L	1
Au-Yeung, R; Chan, TSY; Ip, AHW; Kwong, YL; Pang, AWK	1
Bachy, E; Becker, S; Beldi-Ferchiou, A; Bossard, C; Bouabdallah, R; Cacheux, V; Camus, V; Cartron, G; Casasnovas, O; Cottereau, AS; de Leval, L; Delfau-Larue, MH; Delmer, A; Fataccioli, V; Fourati, S; Gaulard, P; Haioun, C; Lemonnier, F; Letourneau, A; Meignan, M; Missiaglia, E; Moles-Moreau, MP; Parrens, M; Pelletier, L; Régny, C; Robe, C; Safar, V; Voillat, L	1
Batchelor, TT; Grommes, C; Nayak, L; Tun, HW	1
Agostinelli, C; Argnani, L; Broccoli, A; Celli, M; Pellegrini, C; Pileri, S; Zinzani, PL	1
Dickinson, M; Prince, HM	1
Aljijakli, A; Arakelyan, N; Bouallegue, S; Chaoui, D; Genet, P; Sutton, L	1
Duvic, M	1
Kwong, YL	1
Belch, A; Chua, N; Dueck, G; Finch, D; Johnston, J; Prasad, A; Reiman, T; Stewart, D; van der Jagt, R; White, D	1
Beckers, MM; Huls, G	1

Reviews

2 review(s) available for lenalidomide and T-Cell Lymphoma

Article	Year
Introduction of novel agents in the treatment of primary CNS lymphoma. Neuro-oncology, 2019, 02-19, Volume: 21, Issue:3 Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents, Immunological; Burkitt Lymphoma; Central Nervous System Neoplasms; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; Thalidomide; Toll-Like Receptors; TOR Serine-Threonine Kinases; Tumor Escape	2019
Emerging drugs for T-cell lymphoma. Expert opinion on emerging drugs, 2014, Volume: 19, Issue:2 Topics: Alemtuzumab; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Azepines; Brentuximab Vedotin; Histone Deacetylase Inhibitors; Humans; Immunoconjugates; Lenalidomide; Lymphoma, T-Cell; Pyrimidines; Receptor Protein-Tyrosine Kinases; Thalidomide	2014

Article

Year

Introduction of novel agents in the treatment of primary CNS lymphoma.

Neuro-oncology, 2019, 02-19, Volume: 21, Issue:3

Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents, Immunological; Burkitt Lymphoma; Central Nervous System Neoplasms; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; Thalidomide; Toll-Like Receptors; TOR Serine-Threonine Kinases; Tumor Escape

2019

Emerging drugs for T-cell lymphoma.

Expert opinion on emerging drugs, 2014, Volume: 19, Issue:2

Topics: Alemtuzumab; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Azepines; Brentuximab Vedotin; Histone Deacetylase Inhibitors; Humans; Immunoconjugates; Lenalidomide; Lymphoma, T-Cell; Pyrimidines; Receptor Protein-Tyrosine Kinases; Thalidomide

2014

Trials

2 trial(s) available for lenalidomide and T-Cell Lymphoma

Article	Year
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. Blood advances, 2021, 01-26, Volume: 5, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Lymphoma, T-Cell; Middle Aged; Prospective Studies; Rituximab	2021
Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer, 2010, Oct-01, Volume: 116, Issue:19 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Lymphoma, T-Cell; Male; Middle Aged; Recurrence; Thalidomide	2010

Other Studies

7 other study(ies) available for lenalidomide and T-Cell Lymphoma

Article	Year
Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1. Blood, 2022, 03-31, Volume: 139, Issue:13 Topics: Drug Resistance, Neoplasm; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Lymphoma, T-Cell; Multiple Myeloma; Thalidomide; Ubiquitin-Protein Ligases; Ubiquitination	2022
Unique evolution of angioimmunoblastic T cell lymphoma to Epstein-Barr virus-positive plasma cell myeloma. Annals of hematology, 2020, Volume: 99, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cyclophosphamide; Doxorubicin; Epstein-Barr Virus Infections; Etoposide; Herpesvirus 4, Human; Humans; Lenalidomide; Lymphoma, T-Cell; Male; Neoplasms, Second Primary; Positron Emission Tomography Computed Tomography; Prednisolone; Vincristine	2020
Single-agent lenalidomide is effective in the treatment of a heavily pretreated and refractory angioimmunoblastic T-cell lymphoma patient. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:4 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoblastic Lymphadenopathy; Lenalidomide; Lymph Nodes; Lymphoma, T-Cell; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Prednisone; Recurrence; Retreatment; Thalidomide; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine	2014
Bortezomib, lenalidomide and dexamethasone (VRD) combination as salvage therapy in refractory angioimmunoblastic T cell lymphoma. British journal of haematology, 2014, Volume: 164, Issue:5 Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Immunoblastic Lymphadenopathy; Lenalidomide; Lymphoma, T-Cell; Pyrazines; Salvage Therapy; Thalidomide; Tomography, Emission-Computed	2014
Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome. Hematology. American Society of Hematology. Education Program, 2015, Volume: 2015 Topics: Alemtuzumab; Aminopterin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Deoxycytidine; Depsipeptides; Diphtheria Toxin; Disease Progression; Doxorubicin; Electrons; Gemcitabine; Humans; Hydroxamic Acids; Immunotherapy; Incidence; Interleukin-2; Lenalidomide; Lymphoma, T-Cell; Mycosis Fungoides; Pentostatin; Photopheresis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Retinoids; Sezary Syndrome; Stem Cell Transplantation; Thalidomide; United States; Vorinostat	2015
Radiologic and molecular remission of follicular T cell lymphoma treated with lenalidomide. Annals of hematology, 2017, Volume: 96, Issue:3 Topics: Aged; Angiogenesis Inhibitors; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, T-Cell; Male; Positron Emission Tomography Computed Tomography; Remission Induction; Thalidomide; Treatment Outcome	2017
Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide. European journal of haematology, 2013, Volume: 90, Issue:2 Topics: Antineoplastic Agents, Hormonal; Humans; Immunoblastic Lymphadenopathy; Lenalidomide; Lymphoma, T-Cell; Male; Middle Aged; Prednisone; Remission Induction; Thalidomide	2013